期刊文献+

药动学-药效学模型在临床合理用药的应用价值分析 被引量:8

Value of pharmacokinetics-pharmacodynamics model in rational drug use
原文传递
导出
摘要 药动学-药效学(pharmacokinetics-pharmacodynamics,PK-PD)结合模型阐明了时间-药物浓度-效应三者间关系,能较全面地分析和预测特定给药方案下,药物效应随时间的变化情况,对新药研发,药物临床试验及临床合理用药具有重要的参考价值。现从给药方案优化,疗效和不良反应预测,相互作用分析等方面对近年来国内外PK-PD指导临床用药情况进行综述,阐明PK-PD模型对药物合理使用的意义。 Pharmacokinetics-pharmacodynamics(PK-PD)combined model explained the relationship of time-effect-drug concentration in mathematical formula,which could comprehensively analyze and predict a time-response relationship in a certain dosage regimen.PK-PD model valued crucially in drug discovery,clinical trails and rational drug use.This paper analyzed the significance of PK-PD model in medication at home and abroad in recent years,concluding dosage regimen optimizing,predicting efficacy or adverse reactions and drug interactions.More importantly,the value of PK-PD model in rational drug use was well demonstrated.
作者 张敏 方平飞
出处 《中国医院药学杂志》 CAS 北大核心 2017年第9期881-884,818,共5页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金项目(编号:81473411 81573686)
关键词 药动学 药效学 合理用药 药动学-药效学模型 pharmacokinetics pharmacodynamics rational drug use pharmacokinetics-pharmacodynamics model
  • 相关文献

参考文献3

二级参考文献47

  • 1黄晓晖,裘福荣,李俊.厄贝沙坦在健康志愿者体内的药代动力学-药效学结合模型[J].中国药理学通报,2005,21(6):712-715. 被引量:8
  • 2黄晓晖,史军,李俊,谢海棠,郑青山,孙瑞元.药代动力学和药效动力学中数学建模与模拟的基本原理(1)[J].中国临床药理学与治疗学,2007,12(1):82-89. 被引量:9
  • 3ME1BOHM B, DERENDORF H. Pharmacokinetic/pharmaco dynamic studies in drug product development [J]. J Pharm Sci, 2002, 91(1): 18-31.
  • 4RUB1NO C M, AMBROSE P, CIR1NCIONE B, et al. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development [J]. Diagn Microbiol Infect Dis, 2007, 59(1): 67-74.
  • 5DAVIES G R, NUERMERGER E L. Pharmaeokinetics and pbarmacodynamics in the development of anti-tuberculosis drugs [J]. Tuberculosis (Edinb), 2008, 88(sl): 65-74.
  • 6BERTERA F M, MAYER M A, OPEZZO J A, et al. Pharmacokinetic pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: A microdialysis study [J]. J Pharmaco Toxico Methods, 2007, 56(3): 290-299.
  • 7YASSEN A, KAN J, OLOFSEN E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats [J]. J Phannacol Exp Ther, 2006, 319(2): 682-692.
  • 8VALLE M, GARR1DO M J, PAV6N J M, et al. Pharmaco- kinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O- desmetbyltramadol and (-)-O-desmethyltramadol, in rats [J]. J Pharmacol Exp Ther, 2000, 293(2): 646-653.
  • 9FURUYA A, NOZAWA M, GOTOH J, et al. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non- peptide platelet glycoprotein- II b/IIIa (GP II b/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs [J]. J Pharrn Pharmacol, 2002, 54(7): 921-927.
  • 10VAN STEEG T J, FREIJER J, DANHOF M, et al. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline induced tachycardia as a continuous pharmacodynamic endpoint [J]. Br J Pharmacol, 2007, 151 (3): 356-366.

共引文献24

同被引文献97

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部